SGLT2抑制剂Farxiga-话题@MedSci

#SGLT2抑制剂Farxiga#

6篇内容 | 698人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1533467, encodeId=9314153346e90, content=<a href='/topic/show?id=23be16229ce' target=_blank style='color:#2F92EE;'>#SGLT2抑制剂Farxiga#</a>, objectTitle=SGLT2抑制剂Farxiga喜获FDA快速通道称号，以降低心力衰竭或心血管死亡住院风险, objectType=article, longId=197735, objectId=bb3a19e7357e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb3a19e7357e, replyNumber=0, likeNumber=41, createdTime=2020-07-20, rootId=0, userName=天堂的云, userId=b7fa12453417, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb3a19e7357e, moduleTitle=SGLT2抑制剂Farxiga喜获FDA快速通道称号，以降低心力衰竭或心血管死亡住院风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb3a19e7357e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533466, encodeId=024d15334661b, content=<a href='/topic/show?id=23be16229ce' target=_blank style='color:#2F92EE;'>#SGLT2抑制剂Farxiga#</a>, objectTitle=ADA 2020：SGLT2抑制剂Farxiga降低了心力衰竭患者患糖尿病的风险, objectType=article, longId=195939, objectId=e40a195939e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e40a195939e1, replyNumber=0, likeNumber=44, createdTime=2020-06-17, rootId=0, userName=天堂的云, userId=b7fa12453417, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e40a195939e1, moduleTitle=ADA 2020：SGLT2抑制剂Farxiga降低了心力衰竭患者患糖尿病的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e40a195939e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533465, encodeId=ac8a15334653a, content=<a href='/topic/show?id=23be16229ce' target=_blank style='color:#2F92EE;'>#SGLT2抑制剂Farxiga#</a>, objectTitle=FDA批准阿斯利康的SGLT2抑制剂Farxiga，用于治疗射血分数降低的心力衰竭患者, objectType=article, longId=193624, objectId=acac19362471, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acac19362471, replyNumber=0, likeNumber=32, createdTime=2020-05-08, rootId=0, userName=天堂的云, userId=b7fa12453417, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acac19362471, moduleTitle=FDA批准阿斯利康的SGLT2抑制剂Farxiga，用于治疗射血分数降低的心力衰竭患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acac19362471)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533464, encodeId=3f1f153346406, content=<a href='/topic/show?id=23be16229ce' target=_blank style='color:#2F92EE;'>#SGLT2抑制剂Farxiga#</a>, objectTitle=阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga获得FDA优先审查, objectType=article, longId=185842, objectId=eae01858423e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eae01858423e, replyNumber=0, likeNumber=35, createdTime=2020-01-08, rootId=0, userName=天堂的云, userId=b7fa12453417, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eae01858423e, moduleTitle=阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga获得FDA优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eae01858423e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533463, encodeId=c34e1533463a1, content=<a href='/topic/show?id=23be16229ce' target=_blank style='color:#2F92EE;'>#SGLT2抑制剂Farxiga#</a>, objectTitle=2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善, objectType=article, longId=183195, objectId=6133183195fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6133183195fa, replyNumber=0, likeNumber=35, createdTime=2019-11-20, rootId=0, userName=天堂的云, userId=b7fa12453417, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6133183195fa, moduleTitle=2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6133183195fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1533462, encodeId=b27115334626d, content=<a href='/topic/show?id=23be16229ce' target=_blank style='color:#2F92EE;'>#SGLT2抑制剂Farxiga#</a>, objectTitle=阿斯利康的SGLT2抑制剂Farxiga获得FDA批准以减少因心力衰竭而住院的风险, objectType=article, longId=181704, objectId=6557181e048a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6557181e048a, replyNumber=0, likeNumber=29, createdTime=2019-10-23, rootId=0, userName=天堂的云, userId=b7fa12453417, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6557181e048a, moduleTitle=阿斯利康的SGLT2抑制剂Farxiga获得FDA批准以减少因心力衰竭而住院的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6557181e048a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

SGLT2抑制剂Farxiga

2020-05-29

天堂的云 (审核中...)

前往app查看评论内容

#SGLT2抑制剂Farxiga#

SGLT2抑制剂Farxiga喜获FDA快速通道称号，以降低心力衰竭或心血管死亡住院风险

2020-07-20

天堂的云 (审核中...)

前往app查看评论内容

#SGLT2抑制剂Farxiga#

ADA 2020：SGLT2抑制剂Farxiga降低了心力衰竭患者患糖尿病的风险

2020-06-17

天堂的云 (审核中...)

前往app查看评论内容

#SGLT2抑制剂Farxiga#

FDA批准阿斯利康的SGLT2抑制剂Farxiga，用于治疗射血分数降低的心力衰竭患者

2020-05-08

天堂的云 (审核中...)

前往app查看评论内容

#SGLT2抑制剂Farxiga#

阿斯利康的心力衰竭药物SGLT2抑制剂Farxiga获得FDA优先审查

2020-01-08

天堂的云 (审核中...)

前往app查看评论内容

#SGLT2抑制剂Farxiga#

2019 AHA：阿斯利康的SGLT2抑制剂Farxiga在III期临床显示出显著的心力衰竭改善

2019-11-20

天堂的云 (审核中...)

前往app查看评论内容

#SGLT2抑制剂Farxiga#

阿斯利康的SGLT2抑制剂Farxiga获得FDA批准以减少因心力衰竭而住院的风险

2019-10-23

科室
- - 订阅+
  - 更多科室
工具
服务